Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
2 hedge funds and large institutions have $100K invested in Sonnet BioTherapeutics in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
79% less capital invested
Capital invested by funds: $471K → $100K (-$371K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$255K |
| 2 |
Renaissance Technologies
New York
|
+$85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$251K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$80K |
| 3 |
IC
Intersect Capital
San Ramon,
California
|
-$21K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$20K |
| 5 |
FEG
Financial Enhancement Group
Anderson,
Indiana
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $39K | +$85K | +1 | New |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $22K | – | – | – |
|
3
Hudson Bay Capital Management
Stamford,
Connecticut
| $19K | – | – | – |
|
4
BlackRock
New York
| $12K | – | – | – |
|
5
Bank of America
Charlotte,
North Carolina
| $6K | – | – | – |
|
|
QCIG
6
Quad-Cities Investment Group
Davenport,
Iowa
| $2K | – | – | – |
|
|
AFM
7
Anson Funds Management
Dallas,
Texas
| $214 | +$255K | +3 | New |
|
|
8
Ameriprise
Minneapolis,
Minnesota
| – | -$251K | -2 | Closed |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$80K | -1 | Closed |
|
|
10
Dimensional Fund Advisors
Austin,
Texas
| – | -$20K | – | – |
|
|
FEG
11
Financial Enhancement Group
Anderson,
Indiana
| – | -$6K | – | – |
|
|
IC
12
Intersect Capital
San Ramon,
California
| – | -$21K | – | – |
|
SONN Hedge Fund Activity: Q2 2019 in Review
2 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2019, worth a combined $100K — down 79% from $471K a quarter earlier.
Fund positioning in SONN was balanced in Q2 2019: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $255K. The largest seller was Ameriprise, exiting entirely with an estimated $251K sold.
- 2 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $100K of Sonnet BioTherapeutics stock for Q2 2019, down 79% quarter-over-quarter.
- 2 funds opened new Sonnet BioTherapeutics positions in Q2 2019 and 2 closed out, a net change of 0 holders.
- The largest Sonnet BioTherapeutics buyer in Q2 2019 was Anson Funds Management, an estimated $255K added.
- The largest Sonnet BioTherapeutics seller in Q2 2019 was Ameriprise, an estimated $251K sold.
Based on aggregated 13F filings for Q2 2019.